Vol 57, No 1 (2023)
Review Article
Published online: 2022-06-27

open access

Page views 3770
Article views/downloads 1076
Get Citation

Connect on Social Media

Connect on Social Media

COVID-19-related headache and innate immune response — a narrative review

Marcin Straburzyński1, Ewa Kuca-Warnawin2, Marta Waliszewska-Prosół3
Pubmed: 35758225
Neurol Neurochir Pol 2023;57(1):43-52.


Headache is one of the most prevalent, although often underreported, symptoms of coronavirus disease 2019 (COVID-19). It is generally accepted that this symptom is a form of secondary headache due to systemic viral infection. There are several hypotheses that try to explain its aetiopathogenesis. One of the most compelling is related to innate immune response to viral infection. This rationale is supported by similarities to other viral infections and the temporal overlap between immunological reactions and headache. Moreover, several key factors in innate immunity have been shown to facilitate headache e.g. interferons, interleukin (IL) –1-β, IL-6, and tumour necrosis factor. There is also a possibility that the virus causes headache by the direct activation of afferents through pattern recognition receptors (i.e. Toll-like receptor 7). Moreover, some data on post-COVID-19 headache and after vaccination against SARS-CoV-2 infection suggests a similar cytokine-mediated pathomechanism in these clinical situations. Future research should look for evidence of causality between particular immune response factors and headache. Identifying key molecules responsible for headache during acute viral infection would be an important step towards managing one of the most prevalent secondary headache disorders.


Neurologia i Neurochirurgia Polska

Polish Journal of Neurology and Neurosurgery

2023, Volume 57, no. 1, pages: 43–52

DOI: 10.5603/PJNNS.a2022.0049

Copyright © 2023 Polish Neurological Society

ISSN: 0028-3843, e-ISSN: 1897-4260

COVID-19-related headache and innate immune response — a narrative review

Marcin Straburzyński1Ewa Kuca-Warnawin2Marta Waliszewska-Prosół3
1Department of Family Medicine and Infectious Diseases, University of Warmia and Mazury, Olsztyn, Poland
2Department of Pathophysiology and Immunology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
3Department of Neurology, Wroclaw Medical University, Wrocław, Poland

Address for correspondence: Marcin Straburzyński, Department of Family Medicine and Infectious Diseases, University of Warmia and Mazury,
University Clinical Hospital, 30 Warszawska St., 10–082 Olsztyn, Poland; e-mail: marcinstraburzynski@gmail.com

Received: 30.04.2022; Accepted: 24.05.2022; Early publication date: 27.06.2022


Headache is one of the most prevalent, although often underreported, symptoms of coronavirus disease 2019 (COVID-19). It is generally accepted that this symptom is a form of secondary headache due to systemic viral infection. There are several hypotheses that try to explain its aetiopathogenesis. One of the most compelling is related to innate immune response to viral infection. This rationale is supported by similarities to other viral infections and the temporal overlap between immunological reactions and headache. Moreover, several key factors in innate immunity have been shown to facilitate headache e.g. interferons, interleukin (IL) –1-β, IL-6, and tumour necrosis factor. There is also a possibility that the virus causes headache by the direct activation of afferents through pattern recognition receptors (i.e. Toll-like receptor 7). Moreover, some data on post-COVID-19 headache and after vaccination against SARS-CoV-2 infection suggests a similar cytokine-mediated pathomechanism in these clinical situations. Future research should look for evidence of causality between particular immune response factors and headache. Identifying key molecules responsible for headache during acute viral infection would be an important step towards managing one of the most prevalent secondary headache disorders.

Key words: SARS-CoV-2, pain, innate immune response, IL-1β, IL-6, TNF, IFN, TLR-7

(Neurol Neurochir Pol 2023; 57 (1): 43–52)


The coronavirus disease 2019 (COVID-19) pandemic precipitated great interest in the scientific community, prompting an unparalleled development of research data. In published studies, headache has often appeared as the most prevalent neurological complaint related to different aspects of the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has been named as a symptom of COVID-19 [1] or its direct and indirect sequelae [2]. Moreover, headache has been identified as a prognostic factor [3], as well as an adverse reaction to therapeutic interventions and preventive strategies [4].

However, SARS-CoV-2 is a new headache factor only to a limited degree, and the complaint had been studied decades before the current pandemic. Consequently, the purpose of this review was to critically appraise the dataset published over the last two years in this area. Furthermore, we examine the most likely explanations for phenomena described in headache-related literature during the COVID-19 pandemic in the context of evidence accumulated in the past.

Considerations for review methods

Current guidelines describe headache as one of the cardinal COVID-19 symptoms [5]. However, initial reports indicated its low prevalence in infected subjects (11.3%) [6]. It should be underlined that this data was obtained mostly from hospital-based retrospective case series, which are prone to bias resulting from selective data collection by healthcare providers and discriminatory reporting by patients. Consequently, even recently published meta-analyses based on these studies endorse the opinion that headache is not a prevalent acute COVID-19 symptom [7]. However, the above mentioned retrospective studies were followed by prospective research based on structured questionnaires. The latter placed headache among the most prevalent symptoms of COVID-19 (22–72%) [1, 8–11], although rarely an isolated one [12]. What is more, headache may be one of the most universal complaints in SARS-CoV-2 infection, occurring regardless of virus variant [13]. To conclude, the described underreporting has had a profound impact on evidence interpretation. Consequently, studies based on structured questionnaires specifically focused on headache are the ones with lowest bias risk for the purpose of this review.

The symptoms of COVID-19-related headache have been well characterised from the clinical point of view. However, little has been published on the subject of its pathogenesis. Consequently, only hypotheses have been proposed so far. In their comprehensive review, Caronna and Pozo-Rosich proposed several such concepts [14], e.g.:

  • Direct damage to peripheral and central nervous system (CNS) mediated via virus affinity to angiotensin-converting enzyme 2 (ACE2) and its ability to cross the blood-
    -brain barrier (BBB), especially when the latter is further damaged by inflammatory and coagulopathic processes.
  • Hyperinflammation and cytokine storm with the prominent role of interleukin (IL)-6.
  • Trigeminal system activation resulting from overlapping pathways of COVID-19 and primary headache disorders.

To assess data supporting these theories, our review concentrates on two major concepts: time and reference to non-COVID-19 headache scenarios. In the first, our rationale is that headache should occur simultaneously or be slightly preceded by a causal factor. As to the second concept, SARS--CoV-2 pathology shares many, mostly immune, mechanisms with disorders that have troubled humankind for millennia [5].

Table 1. Prevalence of headache in acute viral respiratory tract infections



Number of

Headache prevalence

Viral upper respiratory infection (miscellaneous pathogens)

Liu et al. 2013 [99]



Influenza virus

Yang et al. 2015 [100]




Zlateva et al. 2020 [101]



Respiratory syncytial virus

Widmer et al. 2014 [102]






Human coronaviruses

Zeng et al. 2018 [36]




Lechien et al. 2020 [1]



Pullen et al. 2020 [11]



O’Keefe et al. 2021 [9]



García-Azorín et al. 2021 [10]



Straburzyński et al. 2021 [8]



Headache in COVID-19 vs other viral respiratory tract infections

As mentioned above, SARS-CoV-2 causes headache in 22–72% of subjects, with the majority of prospective studies pointing to a 60–70% prevalence. These percentages are comparable to results from research on infections caused by common viruses, i.e. influenza, metapneumoviruses, respiratory syncytial viruses (RSV) and rhinoviruses (Tab. 1). However, most of these pathogens substantially differ in their biology e.g. the influenza virus can be both neurotropic and non-neurotropic [15]. It seems justified therefore to look for the source of infection-related headache in pathways that are common for all these pathogens, i.e. immune response.

SARS-CoV-2 tissue distribution

The upper respiratory tract, especially nasal ciliated cells, are the primary targets for SARS-CoV-2 in early COVID-19 stages [16]. The sinonasal mucosa is innervated by the first and second branch of the trigeminal nerve. Nerve endings of C and A-delta fibres are immersed in whatever biochemical or inflammatory processes take place in this area.

Viral sinonasal inflammation (acute rhinosinusitis) occurs in response to the replication of the virus in the nasal epithelium. Virus-derived molecules recognised by innate immune cells are referred to as pathogen-associated molecular patterns (PAMP). These structures are highly specific for given types of microorganisms (e.g. there are observations suggesting that the SARS-CoV-2 spike protein may act as a PAMP and cause neuroinflammation [17]). PAMP binding receptors are known as pattern recognition receptors (PRR). It is not fully understood which PRRs are activated by SARS-CoV-2. However, experts suggest that the most probable targets are Toll-like receptors 3 (TLR3) and TLR7, retinoic acid--inducible gene 1 (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) [18]. These key sensors of viral infection are expressed intercellularly and respond to nucleic acids (RNA mostly), although in different ways. TLR3 and TLR7 recognise viral nucleic acid transported by the endosomal pathway (i.e. from outside the cell). RIG-1 and MDA-5 detect viruses that have entered the cell and started producing dsRNA during replication. The evidence for RIG-I and MDA5 expression in trigeminal afferents is lacking, and it seems likely that these neurons do not express TLR3 [19]. However, TLR7 is present on nasal mucosa nociceptors and, what is more, its stimulation in the nasal epithelium leads to brainstem activation [20].

It is worth noting that TLR3, TLR7, RIG-1 and MDA5 are expressed in nasal mucosa lymphoid tissue and nasal epithelial cells, leading to their activation and subsequent production of type I interferons and other pro-inflammatory cytokines [21–24]. Consequently, trigeminal afferents sustain exponential elevation of type I and III interferons (IFNs) followed by IL-1α, IL-1β, tumour necrosis factor (TNF), IL-6, C-X-C motif ligand (CXCL)-8, CXCL-10, CXCL-11, and C-C motif ligand (CCL)-5, followed by the next steps of immune response [25]. In a laboratory setting, this situation was simulated by experiments on an animal model. In that study, sinonasal stimulation with bradykinin caused the nociceptive activation of the trigeminal nucleus caudalis — a key region for headache [26]. This in turn may explain why patients with rhinosinusitis have headache and facial pain. In clinical settings, this was further supported by a study of COVID-19 patients that provided evidence for an association between acute inflammation of the sinonasal mucosa and headache/facial pain [8]. In other words, patients experiencing rhinosinusitis during COVID-19 had significantly higher odds of headache or facial pain. These correlations are multi-level and stretch beyond innate response and nasal cavity, e.g. a retrospective study found that patients experiencing headache and sinonasal symptoms have lower levels of anti-SARS-CoV2 IgG [27].

Figure 1. Schematic depiction of temporal changes in upper respiratory tract (URT) virus replication, innate immune response, and headache in mild/moderate COVID-19. Based on Schultze & Aschenbrenner 2021 [22] and O’Keefe et al. [9]

It has been confirmed that the coronavirus can penetrate different areas of the nervous system. Several mechanisms and routes to cross the BBB and spread within the CNS have been proposed, including virus affinity to ACE2 [14, 28, 29]. Some of these hypotheses assume that SARS-CoV-2 travels along the olfactory or trigeminal route [30], similarly to some neurotropic variants of the influenza virus [31]. Activation of the trigeminal ganglion, trigeminal nucleus caudalis and hypothalamus (among other regions) is considered paramount for some primary headache disorders (e.g. migraine). Consequently, this could explain headache pathomechanism occurring via a direct viral action in the trigeminal system [14, 30]. However, evidence published so far indicates moderate virus presence in the trigeminal ganglion or cranial nerve nuclei in the medulla oblongata [32, 33], and neither meningitis nor encephalitis are prevalent in COVID-19 [7, 34]. It should also be underlined that sole virus presence in CNS does not necessarily cause pain. For example, the human coronavirus is clearly neurotropic [35], and yet very seldom causes headache [36].

Molecules involved in innate immune response to SARS-CoV-2

Viral infections trigger innate and adaptive immune responses. These two reactions, although intertwined, have their own timelines, with innate being swifter and less specific. In other words, an innate reaction occurs at the same time as the first infection symptoms, i.e. headache [8, 9, 11, 18] (Fig. 1). Studies analysing COVID-19-related headache have shed some light on its associations with innate immune response.

For example, in hospitalised patients, some infection symptoms (fever, myalgia,) have been associated with headache [37]. Fever occurs in response to, among others, endogenous pyrogens, such as IL-1, TNF or IL-6 [38]. These molecules are also part of the innate immune response in the upper respiratory tract mucosa in infections caused by the influenza virus, RSV or metapneumovirus [39, 40]. Moreover, IL-1, TNF or IL-6 contribute to calcitonin gene-related peptide (CGRP) release, although the latter phenomenon has been described only in animal cutaneous nociceptors [41].

IFNs are produced in response to SARS-CoV-2 most probably via the activation of toll-like receptors. When analysed in detail, innate immune response to SARS-CoV-2 infection is characterised by moderate levels of type I IFNs [42]. However, these molecules still play an important role in COVID-19. IFN-α (type I) and λ (type III) peak early in the disease course, especially in the nasal epithelium. A meta-analysis currently awaiting publication has shown that the application of type I IFN (β) is the cause of headache in multiple sclerosis patients [43]. IFN-α is also the cause of headache in many subjects treated with this molecule [44]. Moreover, earlier studies also pointed to possible migraine exacerbation by IFN-β therapy [45]. Type-I IFNs also activate mitogen-activated protein kinase – a pathway that is associated with pain processing in the trigeminovascular complex [46].

Type I IFNs initiate immune responses involving interleukin IL-1β, IL-6, TNF and some chemokines (CCL20, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL16) [18]. Consequently, these factors are more likely to participate in the origin of COVID-19-related headache than molecules that gain prominence later in COVID-19 course (CCL2, CCL3, CCL5, CXCL9, CXCL10, IL-1α, IL-17, IFN-β, IFN-γ, IL-10, IL-33) [18].

IL-6 plays an important role in the early phases of COVID-19 [18], and consequently, this particle should be considered as a possible trigger for headache in this infection. There is however contradictory evidence in this regard. On the one hand, IL-6 levels show positive linear correlation with headache intensity in COVID-19 [47]. On the other hand, headache is associated with lower, although still elevated, IL-6 levels [3]. Moreover, IL-6 is considered a key player in severe COVID-19 and cytokine storm [48] — a late complication occurring in a cohort with less prevalent headache. In reference to its nociceptive potential, it should be mentioned that patients with chronic and episodic tension-type headache (TTH) have elevated serum levels of IL-6 [49]. Moreover, this has been shown in animal migraine models to facilitate the excitability of dural afferents and allodynia [50]. It is therefore a molecule that may play an important role in triggering headache in systemic inflammation. Moreover, IL-6 receptor antagonist (tocilizumab) is a drug inducing clinical remission in giant-cell arteritis, a disease with headache as a prominent symptom [51].

TNF is an endogenous pyrogen and cytokine, playing an important role in early immune response to SARS-CoV-2 infection [18]. Moreover, it has been speculated for decades that it is a headache facilitator [52]. Four-hour TNF infusion has been associated with headache occurring in 65% of subjects [53]. Several studies have indicated that TNF may play a role in migraine pathogenesis [54]. It has also been shown to provoke the sensitisation of meningeal nociceptors [55]. Moreover, out of other cytokines analysed in one study, TNF has been most consistently associated with headache in aneurysmal subarachnoid haemorrhage [56].

As described above, time seems to be of great importance in the development of COVID-19-related headache. Since headache occurs early in the disease course, it is in this period that we should look for initiating factors. When analyses involve patients in later stages of the disease, then associations between inflammatory factors and headache are hard to find. For example, one highly comprehensive study found little association between a wide panel of cytokines and chemokines and headache [57]. The only factor associated with headache was, after adjustments, the level of IL-10. This cytokine is an important anti-inflammatory molecule targeted at the moderating effect of, among others, type I IFNs and TNF [58]. Higher levels of IL-10 may then support the hypothesis that IFNs and TNF play an important role in headache at early stages of the disease, and more IL-10 is secreted in later stages to alleviate this effect.

The above-described molecules form only a small fraction of innate immune response. Some elements have not been discussed due to little evidence allowing for their inclusion in this rationale (e.g. prostaglandins, galectins, innate immune cells including mast cells). However, other particles have been also implicated in early response to COVID-19 and associated headache. One study showed that headache in COVID-19 is associated with higher levels of NLR family pyrin domain containing 3 (NLRP3) inflammasome, and the high mobility group box 1 protein (HMGB1) [59]. The latter has been shown to be involved in trigeminal ganglion neuropathic pain [60]. Moreover, inflammasome is activated by SARS-CoV-2, which in turn leads to the activation of IL-1β and IL-18. IL-1β activates and sensitises the trigeminal ganglion [61, 62], while IL-18 may play some role in migraine [63].

In light of the described rationale, it might be surprising that COVID-19-related headache is associated with lower C-reactive protein levels [64, 65] (although these levels were still higher than in healthy subjects). However, it must be remembered that C-reactive protein is an unspecific inflammation marker rising moderately in the early phases of infection, and reaching higher levels when severe disease or complications develop. Therefore, it has probably a weaker association with processes causing headache.

Currently it is hardly possible to touch upon headache without mentioning CGRP. This molecule not only plays a pivotal role in primary headache disorders, but also participates in immune responses. TNF contributes to CGRP release in the trigeminal ganglion [66], while both TNF and IL-1β increase CGRP expression [67]. Moreover, nociceptive sensitisation caused by IL-6 is blocked by olcegepant, a CGRP antagonist [68]. It seems therefore justified to assume that COVID-19-related inflammation may lead to CGRP release at different levels of the trigeminal system [30]. However, in COVID-19 patients, serum levels of CGRP are lower than in healthy controls [69], while another study found no difference in CGRP levels between subjects with and without headache [59]. Finally, anti-CGRP treatments seem to have no effect on COVID-19 course [70].

Table 2. Diagnostic criteria of acute headache attributed to systemic viral infection

A. Headache of any duration (but lasting < 3 months) fulfilling criterion C

B. Both of the following:

  1. systemic viral infection has been diagnosed
  2. no evidence of meningitic or encephalitic involvement

C. Evidence of causation demonstrated by at least two of the following:

  1. headache has developed in temporal relation to onset of systemic viral infection
  2. headache has significantly worsened in parallel with worsening of systemic viral infection
  3. headache has significantly improved or resolved in parallel with improvement in, or resolution of, systemic viral infection
  4. headache has one or both of following characteristics:

a. diffuse pain

b. moderate or severe intensity

D. Not better accounted for by another ICHD-3 diagnosis

Clinical features of COVID-19-related headache

Any headache should be classified according to the International Classification of Headache Disorders — 3 (ICHD-3). As regards COVID-19, it is currently diagnosed as “acute headache attributed to systemic viral infection” (Tab. 2). In some disorders, headache phenotype can contribute to identifying the pathological mechanism underlying this symptom (e.g. thunderclap headache in subarachnoid haemorrhage, postural headache in spontaneous intracranial hypotension [71]). In COVID-19 headache has however little specificity — the majority of patients appear to present symptoms similar to TTH 43–68% [8, 10, 72–75]. That is, pain is mostly bilateral, pressing and dull, and mild to moderate in intensity. This phenotype has been associated with lower C-reactive protein levels than headache with more migraine features (i.e. unilateral, pulsating, moderate to severe) [75]. Migraine phenotype is present in 25–50% of subjects [8, 73, 76], and is associated with a more severe COVID-19 course [14]. There is also some evidence that migraine-like headache in COVID-19 is associated with pre-existing migraine [74]. Accompanying autonomic symptoms (i.e. nausea or vomiting and hypersensitivity to light and sound) are not rare [64]. Non-nasal cranial autonomic symptoms (i.e. conjunctival injection and/or lacrimation, eyelid oedema, forehead and facial sweating, miosis and/or ptosis) occur rarely in the course of this infection. Naturally, nasal congestion and rhinorrhoea [8] are highly prevalent due to sinonasal inflammation. In conclusion, COVID-19-related headache may indicate a more effective and balanced immune response, especially when it resembles TTH.

Headache in COVID-19 has been associated with a better prognosis expressed as lower mortality and shorter disease duration [37, 65], although larger observations still await publication [77]. In COVID-19 α and λ IFNs peak early in a mild to moderate disease course. This might indicate that subjects able to develop this prompt immune response are apparently protected against severe COVID-19. This hypothesis is supported by experiments with rodents, where the administration of interferon I protected against cytokine storm [78]. However, it must be remembered that headache in COVID-19 is merely a symptom, and may herald serious complications e.g. cerebral venous sinus thrombosis [79] or encephalitis [80]. These conditions might be difficult to recognise during COVID-19 if headache is initially the only complaint. There is also some evidence that COVID-19 may lead to unusual changes in pre-existing migraine, e.g. there have been several case-reports of patients developing prolonged or unusual migraine aura during COVID-19 [81]. Consequently, caution is recommended, especially because many patients with COVID-19 complain of apparent ‘red flags’, e.g. mentioning “positional headache” or “worst headache ever” [10]. Moreover, comorbidities may have a strongly negative influence on prognosis [82].

Apart from a few case series, there is very little data on interventions effective in reducing COVID-19-related headache. In one study, paracetamol 1g iv or greater occipital nerve blocks were effective in reducing pain [47]. In another publication, indomethacin (50mg twice daily) was effective in a small case series of patients with acute (n = 21) and persistent COVID-19-related headache (n = 8) [83]. No data on preventive therapies is available, although several particles with potential simultaneously in viral infections and primary headache disorders have been proposed (e.g. low vitamin D3 levels are associated with more frequent headaches [74] and COVID-19 risk [75]).

Post-COVID-19 syndrome and headache

Headache is a common symptom of post-COVID-19 syndrome included in some diagnostic guidelines [84]. A study assessing data from 905 subjects with COVID-19-related headache showed that 31.1% of patients still had headache after one month, 16.8% after three months, and 16% after nine months [2]. These numbers were slightly lower in a recent meta-analysis: 47.1% during the acute phase, 10.6% at three months and 8.4% after six months [85]. Nevertheless, both of these studies indicate that headache in post-COVID-19 syndrome has a poor prognosis. Approximately equal groups in post-COVID-19 headache have migraine and TTH phenotype-headache [2].

The pathomechanism of post-COVD-19 headache is unknown, although there is some evidence that patients with post-COVID may have increased IL-6 levels [86, 87]. Another study indicated elevated levels of IFN-α, TNF, G-CSF, IL-17A, IL-6, IL-1β, while IL-13 and CXCL-10 were decreased [88]. Although no clear association with pre-existing primary headache disorder has been confirmed, several scenarios are possible:

  • persistent secondary headache due to COVID-19
  • first manifestation of previous asymptomatic primary headache disorder
  • exacerbation of previous low-grade primary headache disorder.

Post-vaccination headache

The COVID-19 pandemic has provided further data in the area of headache related to innate immune response, albeit not directly related to infection, but rather to vaccination. A recent meta-analysis including 83 studies of 1.57 million subjects revealed that headache occurs after the first and second COVID-19-vaccination dose in 22% and 29% of patients respectively [4]. Patterns similar to COVID-19 can be observed in cases of vaccine-related headache. Headache occurs early after vaccination [89–92] and is often accompanied by other systemic symptoms (i.e. myalgia and fever [91]). Similarly to COVID-19, headache after vaccination has more often a TTH phenotype, with migraine-like features present in one third of cases. Post-vaccination headache is not vaccine- or even pathogen-specific, i.e. it is present after vector and mRNA vaccinations. Moreover, immunisation against other types of viruses (e.g. influenza [93], human papillomavirus [94], Ebola [95]) is also commonly associated with headache. The risk of headache after COVID-19 vaccination is doubled by a pre--existing primary headache disorder (e.g. migraine) [91, 92].

The above observations may point to a common mechanism of vaccination- and COVID-19-related headache, with the only common denominator being immune response. One study showed that SARS-CoV-2 spike protein, a major antigen in vaccines, may act as a PAMP and cause neuroinflammation [17]. However, pain should be less prevalent after a second vaccine dose, if this mechanism is responsible for headache (when humoral immunity leads to faster spike protein elimination). Another study showed that after the first dose of SARS-CoV-2 mRNA vaccine (BNT162b2) a prompt release of IFN-γ, CXCL-10, IL-6, IL-8, IL-15, CCL-3, CCL-4 is observed, with some changes lasting for more than one week [96]. After the second dose IFN-γ, CXCL-10, IL-15 and IL-6 were elevated to levels several times higher than after the first dose. This pattern is mirrored by headache, which usually occurs within the first 24 hours, remits after a couple of days after the first vaccination [89–92], and is more prevalent after the second dose [4]. As a side issue, it should be mentioned that CCL-2 and IL-3 were not significantly increased throughout the study, TNF concentrations were only slightly higher, and type I and III IFNs were not analysed at all in this study [96].

It is important to remember that headache might be a primary complaint in patients presenting with vaccination complications. Probably the most widely cited source of post-vaccination headache is vector-vaccine-induced immune thrombotic thrombocytopenia (VITT), [4] although even less prevalent complications have been described (e.g. Tolosa-Hunt syndrome [97]). The major difference between headache in VITT and after vaccination is time. Post-vaccination headache occurs in the first 24 hours, while in VITT it occurs after several (7–10) days [98].

Conclusions and future research

Probably the most important question about COVID-19--related headache remains unanswered. It seems that the pandemic has run its primary course and will recur as a milder disease. Reduction in interest from the scientific community will follow. Meanwhile, the mechanism of headache in COVID-19 and the common pathways for other viral infections and primary headache disorders remain unknown.

Our rationale indicates that elements of innate immune response can trigger headache, peak early in COVID-19 alongside headache, and play an important role in protecting against severe disease course, allowing for a better prognosis in subjects with COVID-19-related headache. Consequently, it seems likely that interactions between innate immune response (especially in the sinonasal area) and trigeminal system play a crucial role in the aetiopathogenesis of headache secondary to COVID-19.

Moreover, if innate immune reaction to SARS-CoV-2 can trigger headache, then probably similar pathways are activated in other clinical situations (e.g. infections, immunisation, immunomodulatory treatment, autoimmune disorders). Future research should look for evidence of causality between particular immune response factors and headache. If found, such a correlation could have important clinical consequences for diagnosis and treatment strategies in a wide variety of disorders with prominent immune response.

Conflicts of interest: None.

Funding: None.


  1. Lechien J, Chiesa-Estomba C, Place S, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. Journal of Internal Medicine. 2020; 288(3): 335–344, doi: 10.1111/joim.13089.
  2. Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, et al. Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients. Cephalalgia. 2022 [Epub ahead of print]: 3331024211068074, doi: 10.1177/03331024211068074, indexed in Pubmed: 35166156.
  3. Caronna E, Ballvé A, Llauradó A, et al. Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020; 40(13): 1410–1421, doi: 10.1177/0333102420965157, indexed in Pubmed: 33146036.
  4. Castaldo M, Waliszewska-Prosół M, Koutsokera M, et al. European Headache Federation School of Advanced Studies (EHF-SAS). Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. J Headache Pain. 2022; 23(1): 41, doi: 10.1186/s10194-022-01400-4, indexed in Pubmed: 35361131.
  5. Flisiak R, Horban A, Jaroszewicz J, et al. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, 2022. Pol Arch Intern Med. 2022; 132(3), doi: 10.20452/pamw.16230, indexed in Pubmed: 35352546.
  6. Zhu J, Zhong Z, Ji P, et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health. 2020; 8(2), doi: 10.1136/fmch-2020-000406, indexed in Pubmed: 32371463.
  7. Misra S, Kolappa K, Prasad M, et al. Frequency of neurologic manifestations in COVID-19: a systematic review and meta-analysis. Neurology. 2021; 97(23): e2269–e2281, doi: 10.1212/WNL.0000000000012930, indexed in Pubmed: 34635561.
  8. Straburzyński M, Nowaczewska M, Budrewicz S, et al. COVID-19-related headache and sinonasal inflammation: A longitudinal study analysing the role of acute rhinosinusitis and ICHD-3 classification difficulties in SARS-CoV-2 infection. Cephalalgia. 2022; 42(3): 218–228, doi: 10.1177/03331024211040753, indexed in Pubmed: 34541916.
  9. O’Keefe JB, Tong EJ, O’Keefe GD, et al. Description of symptom course in a telemedicine monitoring clinic for acute symptomatic COVID-19: a retrospective cohort study. BMJ Open. 2021; 11(3): e044154, doi: 10.1136/bmjopen-2020-044154, indexed in Pubmed: 33674374.
  10. García-Azorín D, Sierra Á, Trigo J, et al. Frequency and phenotype of headache in covid-19: a study of 2194 patients. Sci Rep. 2021; 11(1): 14674, doi: 10.1038/s41598-021-94220-6, indexed in Pubmed: 34282206.
  11. Pullen MF, Skipper CP, Hullsiek KH, et al. Symptoms of COVID-19 Outpatients in the United States. Open Forum Infect Dis. 2020; 7(7): ofaa271, doi: 10.1093/ofid/ofaa271, indexed in Pubmed: 33117855.
  12. Westbrook AL, Benedit LC, Frediani JK, et al. Predictive value of isolated symptoms for diagnosis of SARS-CoV-2 infection in children tested during peak circulation of the delta variant. Clin Infect Dis. 2022 [Epub ahead of print], doi: 10.1093/cid/ciac112, indexed in Pubmed: 35271694.
  13. Iacobucci G. Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show. BMJ. 2021; 375: n3103, doi: 10.1136/bmj.n3103, indexed in Pubmed: 34916215.
  14. Caronna E, Pozo-Rosich P. Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research. Curr Pain Headache Rep. 2021; 25(11): 73, doi: 10.1007/s11916-021-00987-8, indexed in Pubmed: 34766205.
  15. Barbosa-Silva MC, Santos LE, Rangel B. The impact of non-neurotropic influenza strains on the brain: a role for microglial priming? J Neurosci. 2018; 38(36): 7758–7760, doi: 10.1523/JNEUROSCI.1368-18.2018, indexed in Pubmed: 30185538.
  16. Ahn JiH, Kim J, Hong SP, et al. Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. J Clin Invest. 2021; 131(13), doi: 10.1172/JCI148517, indexed in Pubmed: 34003804.
  17. Frank MG, Nguyen KH, Ball JB, et al. SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties. Brain Behav Immun. 2022; 100: 267–277, doi: 10.1016/j.bbi.2021.12.007, indexed in Pubmed: 34915155.
  18. Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021; 184(7): 1671–1692, doi: 10.1016/j.cell.2021.02.029, indexed in Pubmed: 33743212.
  19. Zimmer B, Ewaleifoh O, Harschnitz O, et al. Human iPSC-derived trigeminal neurons lack constitutive TLR3-dependent immunity that protects cortical neurons from HSV-1 infection. Proc Natl Acad Sci U S A. 2018; 115(37): E8775–E8782, doi: 10.1073/pnas.1809853115, indexed in Pubmed: 30154162.
  20. Larsson OJ, Kumlien Georén S, Cardell LO. Rapid activation of brainstem nuclei following TLR stimulation of the nasal mucosa. Acta Neurobiol Exp (Wars). 2020; 80(4): 353–357, indexed in Pubmed: 33350987.
  21. Takaki H, Kure S, Oshiumi H, et al. Toll-like receptor 3 in nasal CD103 dendritic cells is involved in immunoglobulin A production. Mucosal Immunol. 2018; 11(1): 82–96, doi: 10.1038/mi.2017.48, indexed in Pubmed: 28612840.
  22. Jha A, Thwaites RS, Tunstall T, et al. Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis. J Allergy Clin Immunol. 2021; 147(2): 694–703.e12, doi: 10.1016/j.jaci.2020.07.012, indexed in Pubmed: 32717253.
  23. Tengroth L, Millrud CR, Kvarnhammar AM, et al. Functional effects of Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cells. PLoS One. 2014; 9(6): e98239, doi: 10.1371/journal.pone.0098239, indexed in Pubmed: 24886842.
  24. Bogefors J, Kvarnhammar AM, Latif L, et al. Retinoic acid-inducible gene 1-like receptors in the upper respiratory tract. Am J Rhinol Allergy. 2011; 25(6): e262–e267, doi: 10.2500/ajra.2011.25.3712, indexed in Pubmed: 22185736.
  25. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58(Suppl S29): 1–464, doi: 10.4193/Rhin20.600, indexed in Pubmed: 32077450.
  26. Koch M, Sertel-Nakajima J, Messlinger K. Responses of spinal trigeminal neurons to noxious stimulation of paranasal cavities - a rat model of rhinosinusitis headache. Cephalalgia. 2021; 41(5): 535–545, doi: 10.1177/0333102420970467, indexed in Pubmed: 33203222.
  27. Vinkenoog M, Steenhuis M, Brinke AT, et al. Associations between symptoms, donor characteristics and IgG antibody response in 2082 COVID-19 convalescent plasma donors. Front Immunol. 2022; 13: 821721, doi: 10.3389/fimmu.2022.821721, indexed in Pubmed: 35296077.
  28. Słyk S, Domitrz I. Neurological manifestations of SARS-CoV-2 — a systematic review. Neurologia i Neurochirurgia Polska. 2020; 54(5): 378–383, doi: 10.5603/pjnns.a2020.0050.
  29. Bratosiewicz-Wąsik J. Neuro-COVID-19: an insidious virus in action. Neurol Neurochir Pol. 2022; 56(1): 48–60, doi: 10.5603/PJNNS.a2021.0072, indexed in Pubmed: 34642927.
  30. Messlinger K, Neuhuber W, May A. Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19. Cephalalgia. 2022; 42(2): 176–180, doi: 10.1177/03331024211036665, indexed in Pubmed: 34407648.
  31. Park CH, Ishinaka M, Takada A, et al. The invasion routes of neurovirulent A/Hong Kong/483/97 (H5N1) influenza virus into the central nervous system after respiratory infection in mice. Arch Virol. 2002; 147(7): 1425–1436, doi: 10.1007/s00705-001-0750-x, indexed in Pubmed: 12111416.
  32. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-
    -CoV-2 invasion as a
    port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021; 24(2): 168–175, doi: 10.1038/s41593-020-00758-5, indexed in Pubmed: 33257876.
  33. Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. The Lancet Neurology. 2020; 19(11): 919–929, doi: 10.1016/s1474-4422(20)30308-2.
  34. Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological Features of Covid-19. N Engl J Med. 2020; 383(10): 989–992, doi: 10.1056/NEJMc2019373, indexed in Pubmed: 32530583.
  35. Desforges M, Le Coupanec A, Brison E, et al. Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans. Adv Exp Med Biol. 2014; 807: 75–96, doi: 10.1007/978-81-322-1777-0_6, indexed in Pubmed: 24619619.
  36. Zeng ZQ, Chen DH, Tan WP, et al. Epidemiology and clinical characteristics of human coronaviruses OC43, 229E, NL63, and HKU1: a study of hospitalized children with acute respiratory tract infection in Guangzhou, China. Eur J Clin Microbiol Infect Dis. 2018; 37(2): 363–369, doi: 10.1007/s10096-017-3144-z, indexed in Pubmed: 29214503.
  37. Trigo J, García-Azorín D, Planchuelo-Gómez Á, et al. Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study. J Headache Pain. 2020; 21(1): 94, doi: 10.1186/s10194-020-01165-8, indexed in Pubmed: 32727345.
  38. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res. 2004; 10(4): 201–222, doi: 10.1179/096805104225006129, indexed in Pubmed: 15373964.
  39. Laham FR, Israele V, Casellas JM, et al. Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy. J Infect Dis. 2004; 189(11): 2047–2056, doi: 10.1086/383350, indexed in Pubmed: 15143472.
  40. Kaiser L, Fritz RS, Straus SE, et al. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol. 2001; 64(3): 262–268, doi: 10.1002/jmv.1045, indexed in Pubmed: 11424113.
  41. Oprée A, Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-α, IL-1β, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. The Journal of Neuroscience. 2000; 20(16): 6289–6293, doi: 10.1523/jneurosci.20-16-06289.2000.
  42. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020; 181(5): 1036–1045.e9, doi: 10.1016/j.cell.2020.04.026, indexed in Pubmed: 32416070.
  43. Pereira LG, Trevisan G, Rodrigues P, et al. Interferon-beta injection in multiple sclerosis patients is related to the induction of headache and flu-like pain symptoms: a systematic review and meta-analysis of randomised controlled trials. Curr Neuropharmacol. 2021 [Epub ahead of print], doi: 10.2174/1570159X19666211101142115, indexed in Pubmed: 34720084.
  44. van Zonneveld M, Flink HJ, Verhey E, et al. HBV 99-01 Study Group. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther. 2005; 21(9): 1163–1171, doi: 10.1111/j.1365-2036.2005.02453.x, indexed in Pubmed: 15854180.
  45. Villani V, Prosperini L, De Giglio L, et al. The impact of interferon beta and natalizumab on comorbid migraine in multiple sclerosis. Headache. 2012; 52(7): 1130–1135, doi: 10.1111/j.1526-4610.2012.02146.x, indexed in Pubmed: 22486199.
  46. Tashiro A, Okamoto K, Bereiter DA. Chronic inflammation and estradiol interact through MAPK activation to affect TMJ nociceptive processing by trigeminal caudalis neurons. Neuroscience. 2009; 164(4): 1813–1820, doi: 10.1016/j.neuroscience.2009.09.058, indexed in Pubmed: 19786077.
  47. Karadaş Ö, Öztürk B, Sonkaya AR, et al. Latent class cluster analysis identified hidden headache phenotypes in COVID-19: impact of pulmonary infiltration and IL-6. Neurol Sci. 2021; 42(5): 1665–1673, doi: 10.1007/s10072-020-04978-2, indexed in Pubmed: 33559789.
  48. Jones SA, Hunter CA. Is IL-6 a key cytokine target for therapy in COVID-19?
    Nat Rev Immunol. 2021; 21(6): 337–339, doi: 10.1038/s41577-021-00553-8, indexed in Pubmed: 33850327.
  49. Koçer A, Koçer E, Memişoğullari R, et al. Interleukin-6 levels in tension headache patients. Clin J Pain. 2010; 26(8): 690–693, doi: 10.1097/AJP.0b013e3181e8d9b6, indexed in Pubmed: 20664340.
  50. Yan J, Melemedjian OK, Price TJ, et al. Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6). Mol Pain. 2012; 8: 6, doi: 10.1186/1744-8069-8-6, indexed in Pubmed: 22273495.
  51. Mollan SP, Paemeleire K, Versijpt J, et al. European Headache Federation recommendations for neurologists managing giant cell arteritis.
    J Headache Pain. 2020; 21(1): 28, doi: 10.1186/s10194-020-01093-7, indexed in Pubmed: 32183689.
  52. Smith RS. The cytokine theory of headache. Med Hypotheses. 1992; 39(2): 168–174, doi: 10.1016/0306-9877(92)90181-b, indexed in Pubmed: 1461182.
  53. Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol. 1988; 6(8): 1328–1334, doi: 10.1200/JCO.1988.6.8.1328, indexed in Pubmed: 3411344.
  54. Trabace S, Brioli G, Lulli P, et al. Tumor necrosis factor gene polymorphism in migraine. Headache. 2002; 42(5): 341–345, doi: 10.1046/j.1526-4610.2002.02104.x, indexed in Pubmed: 12047333.
  55. Zhang XC, Kainz V, Burstein R, et al. Tumor necrosis factor-α induces sensitization of meningeal nociceptors mediated via local COX and p38 MAP kinase actions. Pain. 2011; 152(1): 140–149, doi: 10.1016/j.pain.2010.10.002, indexed in Pubmed: 21036476.
  56. Xu L, Wang W, Lai N, et al. Association between pro-inflammatory cytokines in cerebrospinal fluid and headache in patients with aneurysmal subarachnoid hemorrhage. J Neuroimmunol. 2022; 366: 577841, doi: 10.1016/j.jneuroim.2022.577841, indexed in Pubmed: 35279426.
  57. Trigo J, García-Azorín D, Sierra-Mencía Á, et al. Cytokine and interleukin profile in patients with headache and COVID-19: A pilot, CASE-control, study on 104 patients. J Headache Pain. 2021; 22(1): 51, doi: 10.1186/s10194-021-01268-w, indexed in Pubmed: 34088273.
  58. Rojas JM, Avia M, Martín V, et al. IL-10: a multifunctional cytokine in viral infections. J Immunol Res. 2017; 2017: 6104054, doi: 10.1155/2017/6104054, indexed in Pubmed: 28316998.
  59. Bolay H, Karadas Ö, Oztürk B, et al. HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism. J Headache Pain. 2021; 22(1): 94, doi: 10.1186/s10194-021-01306-7, indexed in Pubmed: 34384355.
  60. Kochi T, Nakamura Y, Ma S, et al. Pretreatment with high mobility group box-1 monoclonal antibody prevents the onset of trigeminal neuropathy in mice with a distal infraorbital nerve chronic constriction injury. Molecules. 2021; 26(7), doi: 10.3390/molecules26072035, indexed in Pubmed: 33918407.
  61. Zhang X, Burstein R, Levy D. Local action of the proinflammatory cytokines IL-1β and IL-6 on intracranial meningeal nociceptors. Cephalalgia. 2012; 32(1): 66–72, doi: 10.1177/0333102411430848, indexed in Pubmed: 22144718.
  62. Binshtok AM, Wang H, Zimmermann K, et al. Nociceptors Are Interleukin-1 Sensors. J Neurosci. 2008; 28(52): 14062–14073, doi: 10.1523/jneurosci.3795-08.2008.
  63. Gong Q, Lin Y, Lu Z, et al. Microglia-Astrocyte Cross Talk through IL-18/IL-18R Signaling Modulates Migraine-like Behavior in Experimental Models of Migraine. Neuroscience. 2020; 451: 207–215, doi: 10.1016/j.neuroscience.2020.10.019, indexed in Pubmed: 33137409.
  64. Membrilla JA, de Lorenzo Í, Sastre M, et al. Headache as a Cardinal Symptom of Coronavirus Disease 2019: A Cross-Sectional Study. Headache. 2020; 60(10): 2176–2191, doi: 10.1111/head.13967, indexed in Pubmed: 32989732.
  65. Gonzalez-Martinez A, Fanjul V, Ramos C, et al. Headache during SARS-CoV-2 infection as an early symptom associated with a more benign course of disease: a case-control study. Eur J Neurol. 2021; 28(10): 3426–3436, doi: 10.1111/ene.14718, indexed in Pubmed: 33417287.
  66. Bowen EJ, Schmidt TW, Firm CS, et al. Tumor necrosis factor-alpha stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem. 2006; 96(1): 65–77, doi: 10.1111/j.1471-4159.2005.03524.x, indexed in Pubmed: 16277606.
  67. Lei Li, Yuan X, Wang S, et al. Mitogen-activated protein kinase pathways are involved in the upregulation of calcitonin gene-related peptide of rat trigeminal ganglion after organ culture. J Mol Neurosci. 2012; 48(1): 53–65, doi: 10.1007/s12031-012-9772-y, indexed in Pubmed: 22528462.
  68. Paige C, Plasencia-Fernandez I, Kume M, et al. A Female-Specific Role for Calcitonin Gene-Related Peptide (CGRP) in Rodent Pain Models. J Neurosci. 2022; 42(10): 1930–1944, doi: 10.1523/JNEUROSCI.1137-21.2022, indexed in Pubmed: 35058371.
  69. Ochoa-Callejero L, García-Sanmartín J, Villoslada-Blanco P, et al. Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. J Endocr Soc. 2021; 5(3): bvaa199, doi: 10.1210/jendso/bvaa199, indexed in Pubmed: 33506161.
  70. Caronna E, José Gallardo V, Alpuente A, et al. Spanish CGRP-COVID Study Group. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications. Neurologia (Engl Ed). 2021; 36(8): 611–617, doi: 10.1016/j.nrleng.2021.03.005, indexed in Pubmed: 34654536.
  71. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013; 33(9): 629–808, doi: 10.1177/0333102413485658, indexed in Pubmed: 23771276.
  72. Kacprzak A, Malczewski D, Domitrz I. Headache attributed to SARS-CoV-2 infection or COVID-19 related headache-not migraine-like problem-original research. Brain Sci. 2021; 11(11), doi: 10.3390/brainsci11111406, indexed in Pubmed: 34827405.
  73. López JT, García-Azorín D, Planchuelo-Gómez Á, et al. Phenotypic characterization of acute headache attributed to SARS-CoV-2: An ICHD-3 validation study on 106 hospitalized patients. Cephalalgia. 2020; 40(13): 1432–1442, doi: 10.1177/0333102420965146, indexed in Pubmed: 33146037.
  74. Porta-Etessam J, Matías-Guiu JA, González-García N, et al. Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals. Headache. 2020; 60(8): 1697–1704, doi: 10.1111/head.13902, indexed in Pubmed: 32666513.
  75. Planchuelo-Gómez Á, Trigo J, de Luis-García R, et al. Deep Phenotyping of Headache in Hospitalized COVID-19 Patients Principal Component Analysis. Front Neurol. 2020; 11, doi: 10.3389/fneur.2020.583870, indexed in Pubmed: 33391152.
  76. Rocha-Filho PA, Magalhães JE. Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia. Cephalalgia. 2020; 40(13): 1443–1451, doi: 10.1177/0333102420966770, indexed in Pubmed: 33146035.
  77. Shapiro R, Gallardo V, Caronna E, et al. The impact of headache disorders on COVID-19 survival: a world population-based analysis. [preprint]. 2021, doi: 10.1101/2021.03.10.21253280.
  78. Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016; 19(2): 181–193, doi: 10.1016/j.chom.2016.01.007, indexed in Pubmed: 26867177.
  79. Dakay K, Cooper J, Bloomfield J, et al. Cerebral venous sinus thrombosis in COVID-19 infection: a case series and review of the literature.
    J Stroke Cerebrovasc Dis. 2021; 30(1): 105434, doi:
    10.1016/j.jstrokecerebrovasdis.2020.105434, indexed in Pubmed: 33190109.
  80. Kania K, Ambrosius W, Tokarz Kupczyk E, et al. Acute disseminated encephalomyelitis in a patient vaccinated against SARS-CoV-2. Ann Clin Transl Neurol. 2021; 8(10): 2000–2003, doi: 10.1002/acn3.51447, indexed in Pubmed: 34480527.
  81. Waliszewska-Prosół M, Budrewicz S. The unusual course of a migraine attack during COVID-19 infection - Case studies of three patients. J Infect Public Health. 2021; 14(7): 903–905, doi: 10.1016/j.jiph.2021.04.013, indexed in Pubmed: 34119843.
  82. Zielińska-Turek J, Jasińska A, Kołakowska J, et al. Clinical features of neurological patients with coronavirus 2019: an observational study of one centre. Neurol Neurochir Pol. 2021; 55(2): 195–201, doi: 10.5603/PJNNS.a2021.0011, indexed in Pubmed: 33528832.
  83. Krymchantowski AV, Silva-Néto RP, Jevoux C, et al. Indomethacin for refractory COVID or post-COVID headache: a retrospective study. Acta Neurol Belg. 2022; 122(2): 465–469, doi: 10.1007/s13760-021-01790-3, indexed in Pubmed: 34546559.
  84. Esposito S, Principi N, Azzari C, et al. Italian intersociety consensus on management of long covid in children. Ital J Pediatr. 2022; 48(1): 42, doi: 10.1186/s13052-022-01233-6, indexed in Pubmed: 35264214.
  85. Fernández-de-Las-Peñas C, Navarro-Santana M, Gómez-Mayordomo V, et al. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: A meta-analysis of the current literature. Eur J Neurol. 2021; 28(11): 3820–3825, doi: 10.1111/ene.15040, indexed in Pubmed: 34327787.
  86. Sun B, Tang N, Peluso MJ, et al. Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations. Cells. 2021; 10(2), doi: 10.3390/cells10020386, indexed in Pubmed: 33668514.
  87. PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022 [Epub ahead of print], doi: 10.1016/S2213-2600(22)00127-8, indexed in Pubmed: 35472304.
  88. Acosta-Ampudia Y, Monsalve DM, Rojas M, et al. Persistent autoimmune activation and proinflammatory state in post-COVID syndrome. J Infect Dis. 2022 [Epub ahead of print], doi: 10.1093/infdis/jiac017, indexed in Pubmed: 35079804.
  89. Göbel CH, Heinze A, Karstedt S, et al. Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain Ther. 2021; 10(2): 1309–1330, doi: 10.1007/s40122-021-00296-3, indexed in Pubmed: 34313952.
  90. Göbel CH, Heinze A, Karstedt S, et al. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun. 2021; 3(3): fcab169, doi: 10.1093/braincomms/fcab169, indexed in Pubmed: 34405142.
  91. Ekizoglu E, Gezegen H, Yalınay Dikmen P, et al. The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic. Cephalalgia. 2022; 42(45): 366–375, doi: 10.1177/03331024211042390, indexed in Pubmed: 34510919.
  92. Sekiguchi K, Watanabe N, Miyazaki N, et al. Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study. Cephalalgia. 2022; 42(3): 266–272, doi: 10.1177/03331024211038654, indexed in Pubmed: 34407651.
  93. Pépin S, Donazzolo Y, Jambrecina A, et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013; 31(47): 5572–5578, doi: 10.1016/j.vaccine.2013.08.069, indexed in Pubmed: 24016810.
  94. Shimabukuro TT, Su JR, Marquez PL, et al. Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019; 144(6), doi: 10.1542/peds.2019-1791, indexed in Pubmed: 31740500.
  95. Tapia M, Sow S, Mbaye K, et al. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases. 2020; 20(6): 719–730, doi: 10.1016/s1473-3099(20)30019-0.
  96. Bergamaschi C, Terpos E, Rosati M, et al. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021; 36(6): 109504, doi: 10.1016/j.celrep.2021.109504, indexed in Pubmed: 34352226.
  97. Chuang TY, Burda K, Teklemariam E, et al. Tolosa-Hunt Syndrome Presenting After COVID-19 Vaccination. Cureus. 2021; 13(7): e16791, doi: 10.7759/cureus.16791, indexed in Pubmed: 34513398.
  98. García-Azorín D, Do TD, Gantenbein AR, et al. Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis. J Headache Pain. 2021; 22(108), doi: 10.1186/s10194-021-01324-5.
  99. Liu WK, Liu Q, Chen DH, et al. Epidemiology and clinical presentation of the four human parainfluenza virus types. BMC Infect Dis. 2013; 13: 28, doi: 10.1186/1471-2334-13-28, indexed in Pubmed: 23343342.
  100. Yang JH, Huang PY, Shie SS, et al. Predictive symptoms and signs of laboratory-confirmed influenza: a prospective surveillance study of two metropolitan areas in Taiwan. Medicine (Baltimore). 2015; 94(44): e1952, doi: 10.1097/MD.0000000000001952, indexed in Pubmed: 26554802.
  101. Zlateva KT, van Rijn AL, Simmonds P, et al. GRACE Study Group. Molecular epidemiology and clinical impact of rhinovirus infections in adults during three epidemic seasons in 11 European countries (2007-2010). Thorax. 2020; 75(10): 882–890, doi: 10.1136/thoraxjnl-2019-214317, indexed in Pubmed: 32820081.
  102. Widmer K, Griffin MR, Zhu Y, et al. Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other Respir Viruses. 2014; 8(3): 347–352, doi: 10.1111/irv.12234, indexed in Pubmed: 24512531.